Ascletis Pharma Inc. (ASCLF)
OTCMKTS
· Delayed Price · Currency is USD
0.8777
0.00 (0.00%)
At close: Apr 24, 2025
Ascletis Pharma Revenue
In the year 2024, Ascletis Pharma had annual revenue of 1.28M CNY, down -97.73%. Ascletis Pharma had revenue of 1.28M in the half year ending December 31, 2024, a decrease of -91.92%.
Revenue
1.28M CNY
Revenue Growth
-97.73%
P/S Ratio
4,429.97
Revenue / Employee
5.55K CNY
Employees
231
Market Cap
778.68M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 43.26M |
Ascletis Pharma News
- 5 days ago - Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA - PRNewsWire
- 27 days ago - Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist - PRNewsWire
- 5 weeks ago - Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025 - PRNewsWire
- 6 weeks ago - Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide - PRNewsWire
- 2 months ago - Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 - PRNewsWire
- 3 months ago - Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update - PRNewsWire
- 4 months ago - Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model - PRNewsWire
- 6 months ago - Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity - PRNewsWire